Latest return on equity
CRISPR Therapeutics Return on equity
Direct answer
CRISPR Therapeutics's return on equity is -26.1%.
The verified market snapshot reports -26.1%.
Bullstory displays the reported value and does not estimate missing data.
Market data checked September 7, 2026.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Return on equity
- -26.1%
Explore related company data
View CRISPR Therapeutics's market capitalizationView CRISPR Therapeutics's price-to-book ratioView CRISPR Therapeutics's 52-week price rangeView CRISPR Therapeutics's revenue growthView CRISPR Therapeutics's profit marginView CRISPR Therapeutics's debt-to-equity ratioView all CRISPR Therapeutics key metricsReturn to CRISPR Therapeutics profile